Bolt Biotherapeutics reports Q4/FY2023 results; cash $128.6M funds through late 2025

Bolt Biotherapeutics, Inc.

Cash, cash equivalents, and marketable securities at $128.6M as of Dec 31, 2023; expected to fund through late 2025.
Collaboration revenue $2.1M in Q4 and $7.9M for FY2023, up from $1.4M and $5.7M prior year.
Loss from operations improved to $19.8M (Q4) and $76.2M (FY2023) vs $21.0M and $90.3M.
BDC-1001 Phase 2 advancing in five HER2-positive tumor cohorts; 29% ORR at RP2D reported at ESMO 2023.
BDC-3042 Phase 1 cleared three dose levels without DLT; now enrolling fourth cohort.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Bolt Biotherapeutics, Inc. reported financial results for the fourth quarter and year ended December 31, 2023.

Period: the fourth quarter and year ended December 31, 2023
Result: reported results

Exact text from the filing

On March 21, 2024, Bolt Biotherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2023.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Bolt Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-034688

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.